Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics, University Children's Hospital Heidelberg, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
Central Institute for Biomedical Technology, Institute for Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
Eur J Pediatr. 2021 Aug;180(8):2401-2408. doi: 10.1007/s00431-021-04031-0. Epub 2021 Mar 25.
Neonatal screening for congenital primary hypothyroidism (CH) may not distinguish between transient (TCH) and permanent dysfunction (PCH), causing potential overtreatment and concerns in affected families. To specify the indication for interruption of therapy, we analysed the German registry "HypoDok" for infants with CH, which oversees 1625 patients from 49 participating centres in Germany and Austria from 1997 until today. A total of 357 patients with a thyroid gland in loco typico were identified and retrospectively grouped according to cessation (TCH, n = 24) or continuation (PCH, n = 333) of L-thyroxine (L-T) treatment at 2 years of age. The receiver operating characteristic (ROC) analysis was performed to identify cutoffs predicting TCH by screening TSH concentrations and L-T dosages. Gestational ages, birth weights and prevalence of associated malformations were comparable in both groups. The cutoff screening TSH concentration was 73 mU/L. The cutoff daily L-T dosage at 1 year was 3.1 μg/kg (90% sensitivity, 63% specificity; 36 μg/day) and at 2 years of age 2.95 μg/kg (91% sensitivity, 59% specificity; 40 μg/day). At 2 years of age, specificity (71%) increased when both of these parameters were considered together.Conclusion: The decision to continue or cease L-T treatment at 2 years of age in CH patients diagnosed in neonatal screening may be based on their screening TSH concentrations and individual L-T dosages at 1 and 2 years of age. Thus, TCH and PCH may be distinguished; overtreatment avoided; and affected families reassured. What is Known: • The course of congenital primary hypothyroidism may be transient, causing potential overtreatment. • The dose of l-thyroxine at 1 or 2 years of age may predict a transient course of primary congenital hypothyroidism. What is New: • TSH screening concentration and l-thyroxine dosages at 1 and 2 years of age represent reliable predictors for transient congenital primary hypothyroidism with higher sensitivity and specificity when considered together in order to select eligible patients who qualify for treatment withdrawal.
新生儿先天性甲状腺功能减退症(CH)的筛查可能无法区分暂时性(TCH)和永久性功能障碍(PCH),从而导致潜在的过度治疗和受影响家庭的担忧。为了明确中断治疗的指征,我们分析了德国“HypoDok”登记处的 CH 婴儿数据,该登记处负责监测德国和奥地利 49 个参与中心的 1625 名患者,自 1997 年至今。共确定了 357 名甲状腺位置正常的患者,并根据 2 岁时是否停止(TCH,n = 24)或继续(PCH,n = 333)L-甲状腺素(L-T)治疗进行回顾性分组。通过筛查 TSH 浓度和 L-T 剂量进行 ROC 分析,以确定预测 TCH 的截断值。两组的胎龄、出生体重和相关畸形的患病率相当。筛选 TSH 浓度的截断值为 73 mU/L。1 岁时的 L-T 日剂量截断值为 3.1 μg/kg(90%敏感性,63%特异性;36 μg/天),2 岁时为 2.95 μg/kg(91%敏感性,59%特异性;40 μg/天)。2 岁时,当同时考虑这两个参数时,特异性(71%)增加。结论:在新生儿筛查中诊断出的 CH 患者,在 2 岁时决定继续或停止 L-T 治疗,可依据其筛查 TSH 浓度和 1 岁和 2 岁时的 L-T 剂量。这样,就可以区分 TCH 和 PCH,避免过度治疗,并使受影响的家庭放心。已知情况:•先天性甲状腺功能减退症的病程可能是暂时的,导致潜在的过度治疗。•1 岁或 2 岁时的 L-甲状腺素剂量可能预测原发性先天性甲状腺功能减退症的暂时性病程。新情况:•1 岁和 2 岁时的 TSH 筛查浓度和 L-甲状腺素剂量是可靠的预测指标,当一起考虑时,敏感性和特异性更高,可选择符合停药条件的合格患者。